An Overview Of Amicus Therapeutics And The Products They Develop

Amicus Therapeutics is a multinational biotechnology firm that has its corporate headquarters located in the town of Cranberry, New Jersey in the United States. Its official name is Amicus Therapeutics Incorporated and it is found on 1 Cedar Brook Drive, Cranberry, New Jersey, 08512 USA. Amicus Therapeutics has a strong international presence in Europe. It has office and research and development facilities in Munich, Germany, Madrid, Spain, Amsterdam, Netherlands, Milan, Italy, and Le Defense, France. The international headquarters of Amicus Therapeutics is found in Buckinghamshire, England.

Amicus Therapeutics specializes in the research, development and production of new medicines for the treatment of rare diseases as well as orphan diseases. Rare and orphan diseases are diseases that are considered to be uncommon and affect a small amount of the population. Amicus Therapetutics is taking the lead in studying how new drugs can provide relief to some of the symptoms of those afflicted with rare disorders.

One of the ways that Amicus Therapeutics is leading the way for curing uncommon and orphan diseases is by creating a personalized approach to medical treatment. One of its drugs called Migalastat, which is in the late development stage uses a person’s unique genetic makeup to help cure Fabry disease. Another drug currently in development by Amicus Therapeutics is called SD-101. If approved and deemed effective, it will be the first drug available on the market to treat Epidermolysis Bullosa, which is a very rare genetic connective tissue disease.

Other biotechnology developments and products developed by Amicus includes the Chaperone-Advanced Replacement Therapy system. This process and technology helps researchers study and develop cures for rare disorders such as Pompe disease and Fabry disease. The Chaperone-Advanced Replacement Therapy created by Amicus Therapeutics is also helping pave the way for new developments in enzyme replacement therapy products which can result in new drugs for lysosomal storage disorders.

Amicus Therapeutics is led by John F. Crowley who serves as the board chairman and chief executive officer. Mr. Bradley L. Campbell serves as the president of the firm and also acts as its chief operating officer. The chief financial officer at Amicus is Chip Baird.

Leave a Reply